Our Journey to Microbiome Innovation
At Perseus Biomics, we're driven by a bold vision: empowering researchers and clinicians to tap into the microbiome’s full potential. Our roadmap is not just a plan—it's our commitment to delivering transformative solutions that help clinical, research, and industrial labs thrive.
2020
Founded in 2020 in Tienen, Belgium, with a vision of revolutionizing microbiome analysis
We founded Perseus Biomics in 2020 at our headquarters in Tienen, Belgium, developing DynaMAP — an optical mapping-based technology delivering unmatched precision in microbiome profiling.
Launched our strategic partnership with Zeiss Ventures as lead investor
Zeiss and Perseus Biomics establish a strategic partnership focused on optical mapping for microbiome applications.
2021
EIC Accelerator Champion – Recognized for groundbreaking innovation by the European Innovation Council
Securing this recognition enabled us to accelerate the development and validation of our DynaMAP technology, laying the foundation for fast market entry and our strategic partnership collaborations.
Established an internationally renowned Scientific Advisory Board
We have assembled a distinguished Scientific Advisory Board, comprising leading experts who guide our innovation and strategic direction. Their collective expertise ensures that Perseus Biomics remains at the forefront of microbiome research and innovation.
2022
Our rapidly growing team operates across 8 countries, bringing together unique perspectives and skills, fueling our innovation and operational excellence.
Expanded our international team significantly, building essential operational expertise
Acceleration of R&D, DynaMAP optimization and technology validation
These efforts paved the way for commercial readiness, ensuring robust performance and scalability. At the same time, we expanded industry collaborations to refine our approach and align with market needs.
2023
Confirmed high accuracy, reproducibility, and commercial readiness through extensive testing, while benchmarking against traditional methods to ensure performance consistency.
Completion of DynaMAP validation through beta testing and industry benchmarking
Advancing our technology with the first prototype of a benchtop device
In 2023, we introduced the first prototype of our benchtop device, laying the groundwork for the future MetaMAP device, bringing high-resolution microbiome analysis closer to end users.
2024
Launching commercial operations with Microbiome Profiling Services available across Europe
Perseus Biomics has officially launched commercial operations, making our microbiome profiling services available across Europe to support applications in personalized nutrition, biotics and food development, epidemiology, and precision medicine industries.
A new chapter begins as Perseus Biomics finds its home in Leuven
As Perseus Biomics continues to grow, we’ve moved our headquarters to Bioincubator in Leuven, a thriving hub of innovation. This expansion marks a new chapter in our journey, bringing us closer to leading research institutions, industry partners, and the heart of European biotech.
2025
Perseus Biomics was named a Probiota Pioneers Winner, highlighting our breakthrough work in microbiome technology. This recognition reinforces our commitment to advancing precision microbiome profiling and driving the future of personalized health and strain-resolved biotics development.
Recognized for innovation as Probiota Pioneers Winners
Launching MetaMAP and expanding in-lab microbiome profiling
In 2025, we are launching MetaMAP, our fully automated benchtop device powered by DynaMAP technology, designed to make high-precision microbiome analysis more accessible.
To be continued...
Perseus Biomics in the Spotlight: News & Updates
Watch our 2-minute DynaMAP technology video
Meet DynaMAP™ Technology
Get the latest insights into cutting-edge microbiome profiling. Download our Profiling Report and DynaMAP White Paper to see how precision, high sensitivity, and specificity come together to advance microbiome research.
